drugset / Trial / NCT03783416
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
Phase 1
Recruiting
72 enrolled
Queen Mary University of London
Takeda Pharmaceuticals International, Inc. · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
Timeline
- Start
- 2020-06-15
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | — | Oral |